A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2015 Jan 30

PMID 25632005

Citations 66

Authors

Tie Zheng Hou

Omar S Qureshi

Chun Jing Wang

Jennifer Baker

Stephen P Young

Lucy S K Walker

David M Sansom

Affiliations

Soon will be listed here.

Abstract

Manipulation of the CD28/CTLA-4 pathway is at the heart of a number of immunomodulatory approaches used in both autoimmunity and cancer. Although it is clear that CTLA-4 is a critical regulator of T cell responses, the immunological contexts in which CTLA-4 controls immune responses are not well defined. In this study, we show that whereas CD80/CD86-dependent activation of resting human T cells caused extensive T cell proliferation and robust CTLA-4 expression, in this context CTLA-4 blocking Abs had no impact on the response. In contrast, in settings where CTLA-4(+) cells were present as "regulators," inhibition of resting T cell responses was dependent on CTLA-4 expression and specifically related to the number of APC. At low numbers of APC or low levels of ligand, CTLA-4-dependent suppression was highly effective whereas at higher APC numbers or high levels of ligand, inhibition was lost. Accordingly, the degree of suppression correlated with the level of CD86 expression remaining on the APC. These data reveal clear rules for the inhibitory function of CTLA-4 on regulatory T cells, which are predicted by its ability to remove ligands from APC.

Citing Articles

Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.

Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A Int J Mol Sci. 2025; 26(1.

PMID: 39795946 PMC: 11719825. DOI: 10.3390/ijms26010088.

Congenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans.

Allard-Chamard H, Hillier K, Ramseier M, Bertocchi A, Kaneko N, Premo K Blood Adv. 2024; 9(3):520-532.

PMID: 39626280 PMC: 11814514. DOI: 10.1182/bloodadvances.2024013267.

Rapid turnover of CTLA4 is associated with a complex architecture of reversible ubiquitylation.

Tey P, Dufner A, Knobeloch K, Pruneda J, Clague M, Urbe S J Cell Biol. 2024; 224(1).

PMID: 39404738 PMC: 11486831. DOI: 10.1083/jcb.202312141.

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.

Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W Biomedicines. 2024; 12(9).

PMID: 39335671 PMC: 11429153. DOI: 10.3390/biomedicines12092158.

Case Report: Aplastic anemia related to a novel variant.

Hall G, Markle J, Maiarana J, Martin P, Rothman J, Sleasman J Front Pediatr. 2024; 12:1434076.

PMID: 39220156 PMC: 11363706. DOI: 10.3389/fped.2024.1434076.

References

Masteller E, Chuang E, Mullen A, Reiner S, Thompson C . Structural analysis of CTLA-4 function in vivo. J Immunol. 2000; 164(10):5319-27. DOI: 10.4049/jimmunol.164.10.5319. View

Rudd C . The reverse stop-signal model for CTLA4 function. Nat Rev Immunol. 2008; 8(2):153-60. DOI: 10.1038/nri2253. View

Cederbom L, Hall H, Ivars F . CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000; 30(6):1538-43. DOI: 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X. View

Reis e Sousa C . Dendritic cells as sensors of infection. Immunity. 2001; 14(5):495-8. DOI: 10.1016/s1074-7613(01)00136-4. View

Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View

Markovic-Plese S, Cortese I, Wandinger K, McFarland H, Martin R . CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest. 2001; 108(8):1185-94. PMC: 209525. DOI: 10.1172/JCI12516. View

Walker L, Ausubel L, Chodos A, Bekarian N, Abbas A . CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J Immunol. 2002; 169(11):6202-9. DOI: 10.4049/jimmunol.169.11.6202. View

Vijayakrishnan L, Slavik J, Illes Z, Greenwald R, Rainbow D, Greve B . An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004; 20(5):563-75. DOI: 10.1016/s1074-7613(04)00110-4. View

Linsley P, Clark E, Ledbetter J . T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A. 1990; 87(13):5031-5. PMC: 54255. DOI: 10.1073/pnas.87.13.5031. View

10.

Linsley P, Brady W, Grosmaire L, Aruffo A, Damle N, Ledbetter J . Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173(3):721-30. PMC: 2118836. DOI: 10.1084/jem.173.3.721. View

11.

Azuma M, Ito D, Yagita H, Okumura K, Phillips J, Lanier L . B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993; 366(6450):76-9. DOI: 10.1038/366076a0. View

12.

Sansom D, Wilson A, Boshell M, Lewis J, Hall N . B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation. Immunology. 1993; 80(2):242-7. PMC: 1422204. View

13.

Hathcock K, Laszlo G, Pucillo C, Linsley P, Hodes R . Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 1994; 180(2):631-40. PMC: 2191623. DOI: 10.1084/jem.180.2.631. View

14.

Boise L, Minn A, Noel P, June C, Accavitti M, LINDSTEN T . CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995; 3(1):87-98. DOI: 10.1016/1074-7613(95)90161-2. View

15.

Krummel M, Allison J . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2):459-65. PMC: 2192127. DOI: 10.1084/jem.182.2.459. View

16.

Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K . Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995; 270(5238):985-8. DOI: 10.1126/science.270.5238.985. View

17.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

18.

Schmidt D, Goronzy J, Weyand C . CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996; 97(9):2027-37. PMC: 507276. DOI: 10.1172/JCI118638. View

19.

Walunas T, Bakker C, Bluestone J . CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996; 183(6):2541-50. PMC: 2192609. DOI: 10.1084/jem.183.6.2541. View

20.

Tivol E, Boyd S, McKeon S, Borriello F, Nickerson P, Strom T . CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol. 1997; 158(11):5091-4. View